meldonium

DRUG4 trials

Sponsors

Pauls Stradins Clinical University Hospital, Joint Stock Company "Grindeks", Kidney Cancer Research Bureau, Enhanced Emirates Limited

Conditions

Chronic coronary heart disease (stable angina)Chronic heart failure with preserved ejection fractionFatigue Related to Cancer TreatmentKidney CancerRenal Cell Cancer MetastaticSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes

Phase 1

Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue

CompletedNCT06648902

Kidney Cancer Research BureauFatigue Related to Cancer Treatment, Kidney Cancer, Renal Cell Cancer Metastatic

Start: 2022-02-01End: 2024-09-01Updated: 2024-10-18

Phase 4

The role of meldonium and individualized physical activities in the treatment of patients with heart failure

Not yet recruitingCTIS2023-509804-14-00

Pauls Stradins Clinical University HospitalChronic heart failure with preserved ejection fraction

Target: 200Updated: 2024-03-27

Unknown Phase

Mildronate - Efficacy And Safety Of Treatment For Chronic Coronary Heart Disease (Stable Angina) I - MILSS I

Active, not recruitingEUCTR2007-005179-32-LV

Joint Stock Company "Grindeks"Chronic coronary heart disease (stable angina)

Start: 2008-09-15Updated: 2012-03-19

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

Enrolling by invitationNCT07568574

Enhanced Emirates LimitedSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes

Start: 2026-03-12End: 2033-03-01Target: 60Updated: 2026-05-06